For US Healthcare Providers

For US Healthcare Providers

Full Prescribing Information

Choose A Condition:

WHAT IS SIMPONI ARIA® (golimumab)?

SIMPONI ARIA® is the only IV anti-TNF biologic approved for the treatment of PsA in patients 2 years of age and older, adult patients with moderately to severely active RA in combination with MTX, and adult patients with active AS.¹

SIMPONI ARIA® has:

  • 10+ years of experience with an estimated 64,000 patients treated in the United States across all approved indications²
  • Improvement in signs and symptoms in adult patients with PsA and RA (ACR20 response at Week 14) and AS (ASAS20 response at Week 16)¹

    First LogoThe first and only anti-TNFα biologic with improvement in both the mental and physical components of SF-36 across PsA, RA, and AS in adult patients, and improvement in fatigue as measured by FACIT-F across PsA and RA in adult patients

  • Demonstrated safety profile¹
  • An infusion experience you can control¹An efficient 30-minute infusion given at Weeks 0 and 4, then every 8 weeks thereafter—as few as 6 times a year"Efficient" is defined as the total amount of time required to infuse.Weight-based dosing (2 mg/kg) for adult patientsNo reconstitution required
  • Support for your patients and your practice Find out more about Access and AffordabilityJanssen CarePath Contract Purchase Program

Learn more about SIMPONI ARIA® for:

RA

Adult Patients with
Moderately to Severely
Active Rheumatoid Arthritis

PsA

ACTIVE PSORIATIC ARTHRITIS IN PATIENTS 2 YEARS AND OLDER

AS

ADULT PATIENTS WITH ACTIVE 
ANKYLOSING SPONDYLITIS